Amlodipine Besylate |
Catalog No.GC13146
One-Click Copy Product Info
|
Block of L-type calcium channel
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 111470-99-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Amlodipine besylate is a long-acting Ca2+ channel blocker that reduce blood pressure as an antihypertensive drugs.
Calcium channel is an ion channel that selectively permeable to calcium ions. It serves vital functions in cellular signal transduction.
In cortical neurons, treatment of amlodipine besylate (<= 5 um) rescued the viability of H(2) O(2) injured cell and elevated the free radicals levels. Amlodipine besylate exhibits neuroptorective effects, such as reducing oxidative stress, promoting survival signals and blocking death signals. [1] It also showed proliferative effect on human epidermoid carcinoma A431 cells.[2]
In patient with exertional angina, amlodipine besylate reduced the total peripheral resistance and myocardial oxygen demand. In cat orally treated with amlodipine besylate daily, the average indirect systolic blood pressure were decreased without significant body weight/serum creatinine/potassium concentrations changes. [3]
References:
[1] Lee YJ, Park HH, Koh SH, Choi NY, Lee KY. Amlodipine besylate and amlodipine camsylate prevent cortical neuronal cell death induced by oxidative stress. J Neurochem. 2011 Dec;119(6):1262-70. doi: 10.1111/j.1471-4159.2011.07529.x.
[2] Yoshida J, Ishibashi T, Nishio M. Antiproliferative effect of Ca2+ channel blockers on human epidermoid carcinoma A431 cells. Eur J Pharmacol. 2003 Jul 4;472(1-2):23-31.
[3] Henik RA, Snyder PS, Volk LM. Treatment of systemic hypertension in cats with amlodipine besylate. J Am Anim Hosp Assoc. 1997 May-Jun;33(3):226-34.
| Cas No. | 111470-99-6 | SDF | |
| Chemical Name | benzenesulfonic acid;3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate | ||
| Canonical SMILES | CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.C1=CC=C(C=C1)S(=O)(=O)O | ||
| Formula | C20H25ClN2O5.C6H6O3S | M.Wt | 567.05 |
| Solubility | ≥ 26.05mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7635 mL | 8.8176 mL | 17.6351 mL |
| 5 mM | 352.7 μL | 1.7635 mL | 3.527 mL |
| 10 mM | 176.4 μL | 881.8 μL | 1.7635 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)